Clinical characteristics of 1217 patients with CD20+ B-cell lymphomas
| Characteristic . | Patients, no. (%) . |
|---|---|
| Age | |
| < 70 y | 777 (63.8) |
| ≥ 70 y | 440 (36.2) |
| Sex | |
| Male | 648 (53.2) |
| Female | 569 (46.8) |
| DLBCL | 944 (81.6) |
| Other B-cell lymphoma | 213 (18.4) |
| Bulky disease | 462 (38.0) |
| Extranodal sites | |
| > 1 | 212 (17.4) |
| B-symptoms | |
| Yes | 397 (32.6) |
| LDH | |
| > UNV | 602 (49.5) |
| ECOG performance status | |
| > 1 | 174 (14.3) |
| Stage | |
| III or IV | 614 (50.5) |
| Bone marrow involvement | 73 (6.0) |
| IPI | |
| 3-5 | 507 (41.7) |
| Characteristic . | Patients, no. (%) . |
|---|---|
| Age | |
| < 70 y | 777 (63.8) |
| ≥ 70 y | 440 (36.2) |
| Sex | |
| Male | 648 (53.2) |
| Female | 569 (46.8) |
| DLBCL | 944 (81.6) |
| Other B-cell lymphoma | 213 (18.4) |
| Bulky disease | 462 (38.0) |
| Extranodal sites | |
| > 1 | 212 (17.4) |
| B-symptoms | |
| Yes | 397 (32.6) |
| LDH | |
| > UNV | 602 (49.5) |
| ECOG performance status | |
| > 1 | 174 (14.3) |
| Stage | |
| III or IV | 614 (50.5) |
| Bone marrow involvement | 73 (6.0) |
| IPI | |
| 3-5 | 507 (41.7) |
DLBCL indicates diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; UNV, upper normal value; ECOG, Eastern Cooperative Oncology Group; and IPI, International Prognostic Index.